Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ironwood Pharmaceuticals (IRWD) EBITDA (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed EBITDA for 16 consecutive years, with -$77.0 million as the latest value for Q4 2025.

  • Quarterly EBITDA fell 344.49% to -$77.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $14.7 million through Dec 2025, down 84.21% year-over-year, with the annual reading at $14.7 million for FY2025, 84.21% down from the prior year.
  • EBITDA hit -$77.0 million in Q4 2025 for Ironwood Pharmaceuticals, down from $75.5 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $391.3 million in Q2 2021 to a low of -$1.1 billion in Q2 2023.
  • Historically, EBITDA has averaged -$7.7 million across 5 years, with a median of $39.4 million in 2021.
  • Biggest five-year swings in EBITDA: soared 1452.54% in 2021 and later crashed 3038.18% in 2023.
  • Year by year, EBITDA stood at $41.4 million in 2021, then grew by 18.11% to $48.9 million in 2022, then dropped by 23.08% to $37.6 million in 2023, then dropped by 16.22% to $31.5 million in 2024, then plummeted by 344.49% to -$77.0 million in 2025.
  • Business Quant data shows EBITDA for IRWD at -$77.0 million in Q4 2025, $75.5 million in Q3 2025, and $45.3 million in Q2 2025.